Home » Posts tagged with » Mene Pangalos
AstraZeneca gets FDA breakthrough status for Farxiga in CKD

AstraZeneca gets FDA breakthrough status for Farxiga in CKD

AstraZeneca has been granted breakthrough therapy designation (BTD) for Farxiga (dapagliflozin) from the US Food and Drug Administration (FDA) for the treatment of patients with chronic kidney disease (CKD), irrespective of type 2 diabetes (T2D). According to the US Centers for Disease Control and Prevention (CDC), chronic kidney disease is a serious, progressive condition defined […]

AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics

Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The financial terms of the deal were not disclosed. AstraZeneca intends to take the PCSK9 inhibitor program into clinical trials in 2021 for dyslipidemia and also familial hypercholesterolemia. People having dyslipidemia, […]

Continue reading …
COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response

COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001 clinical trial showed the ChAdOx1 nCoV-19 vaccine (AZD1222) to be well tolerated besides generating strong responses in all evaluated participants against the COVID-19 causing SARS-CoV-2 virus. The early-stage COVID-19 vaccine trial is being led by Oxford University, […]

Continue reading …
Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI

AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults after an acute myocardial infarction (MI) or heart attack. The fast track designation for the oral once-daily sodium-glucose co-transporter-2 (SGLT2) inhibitor is based on […]

Continue reading …
Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle

Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma acquisition news. Financial details of the two deals have not been disclosed. The divestments are being taken up in an effort to wrap up the $63 billion AbbVie acquisition of […]

Continue reading …
FDA approves AstraZeneca’s FASENRA self-administration via FASENRA Pen

AstraZeneca has bagged approval from the US Food and Drug Administration (FDA) for the self-administration of FASENRA (benralizumab) through FASENRA Pen, a pre-filled, single-use auto-injector, for the add-on maintenance treatment of severe asthma in patients aged 12 years and older, and with an eosinophilic phenotype. FASENRA is a monoclonal antibody which directly binds to the […]

Continue reading …